Trial Profile
BEL114674: A 2 Year Study of Efficacy and Safety of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Belimumab (Primary)
- Indications Membranous glomerulonephritis
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 18 Sep 2014 New trial record